Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab

A Kuuliala, R Nissinen, H Kautiainen, H Repo, M Leirisalo-Repo

Background: Treatment with infliximab induces a rapid therapeutic response in most patients with active rheumatoid arthritis. Factors predicting good response are not well known.

Objective: To study the predictive value of baseline level of soluble interleukin 2 receptor (sIL2R), a marker of lymphocyte activation, on the treatment response.

Methods: 24 patients with active rheumatoid arthritis received intravenous infusions of infliximab at study entry, at two weeks, at six weeks, and at eight week intervals thereafter. Outcome was evaluated at six weeks and 22 weeks. Clinical assessment and standard laboratory tests were made and the DAS28 disease activity score was calculated. Serum sIL2R level at entry was measured by automated immunoassay analyser (Immulite®). The mean change in DAS28 score from entry to six weeks and 22 weeks was calculated and related to sIL2R level using baseline adjusted robust regression analysis.

Results: Baseline level of serum sIL2R (mean (SD), 621 (325) U/ml) did not correlate with baseline DAS28 score (r = 0.24 (95% confidence interval, −0.18 to 0.58)). At six weeks DAS28 scores improved, with a mean change of −2.53 (−3.08 to −1.98) (p < 0.001). This change was predicted by low baseline sIL2R level (regression coefficient per 100 U/ml: 0.205 (0.003 to 0.407) (p = 0.047)). At 22 weeks the DAS28 scores improved, with a mean change of −2.26 (−2.75 to −1.77) (p < 0.001). The change was not predicted by baseline sIL2R level.

Conclusions: Low baseline sIL2R level may predict a rapid clinical response in patients with refractory rheumatoid arthritis treated with infliximab.

METHODS

This study comprises 24 patients with chronic active rheumatoid arthritis. Treatment with all conventional DMARDs had failed. Nineteen patients (79%) were on low dose prednisolone (<15 mg/day). After starting infliximab, DMARD treatment was continued with minor modifications during the study period.

All patients gave their informed consent for participation in the study. The study protocol was approved by the ethics committee of the Helsinki University Central Hospital.

The patients received infliximab infusions (3–4 mg/kg) at entry, and at two weeks, six weeks, 14 weeks, and 22 weeks. The outcome was assessed at six weeks and 22 weeks (one patient died before the 22 week check up visit). Swollen and tender joints were counted. Patient’s assessment of pain, and patient’s and physician’s global assessments were recorded on a 10 cm visual analogue scale. The patients filled in the Finnish version of the Stanford Health Assessment Questionnaire (HAQ) and the HAQ score was calculated.

Abbreviations: DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; sIL2R, soluble interleukin 2 receptor

Rheumatoid arthritis is a systemic autoimmune disease characterised by polyarticular joint inflammation. The disease is heterogeneous with respect to clinical features, genetic background, and immunopathogenesis. The pathogenesis of rheumatoid arthritis is incompletely understood. It involves collaboration between dendritic cells, T cells, and monocytes/macrophages, which may initiate and perpetuate immune activation. Activated CD4+ T cells in the synovium stimulate monocytes and macrophages which produce proinflammatory cytokines, causing synovial inflammation. The synovium can have features of lymphocytic follicles. Indeed, T cells are the most abundant cells in the pannus.

Upon activation, T cells express on their surface interleukin 2 receptor (IL2R) which is shed from the cells and can be detected as a soluble form of IL2R (sIL2R) in synovial fluid and in serum. Activation of T lymphocytes can be evaluated by measuring circulating levels of sIL2R.

A key proinflammatory cytokine in rheumatoid inflammation is tumour necrosis factor (TNF). Monocytes and macrophages are the main source of TNF. The blockade of TNF with infliximab, a chimeric monoclonal anti-TNF antibody, results in a rapid clinical response in the majority of rheumatoid patients. However, only 20–40% of the patients achieve a good clinical response (>ACR50). In the rest of the patients, the effect is only modest or is not observed at all. The reasons for varying responses are largely unknown, but inflammatory and immunological heterogeneity of patients with rheumatoid arthritis might be one explanation.

We have recently presented data suggesting that low baseline serum sIL2R levels may predict early remission in patients with early active DMARD-naive rheumatoid arthritis treated with a single DMARD. This prompted us to study whether baseline sIL2R level serves as a predictor of early treatment response to treatment with infliximab in rheumatoid patients refractory to conventional DMARDs. We reasoned that strong lymphocyte activation, as defined by high levels of sIL2R in the circulation, may, by intensifying macrophage TNF production, delay the clinical response to, or even render the patient refractory to, treatment with infliximab. Here we report that low circulating sIL2R level may predict rapid response to infliximab treatment.
Erythrocyte sedimentation rate (ESR) and serum C reactive protein concentrations were measured using standard laboratory methods. The DAS28 disease activity score was calculated. Immediately before the first infliximab infusion, blood was collected into EDTA, and plasma was separated by centrifugation and frozen at −20°C. The sIL2R levels were measured by Immulite® automated immunoassay analyser (DPC, Los Angeles, California, USA). The sIL2R measurements were carried out blinded, without knowledge of the clinical data.

Pearson correlation coefficients were calculated for serum sIL2R level and baseline DAS28 score. The changes in DAS28 scores, with 95% confidence intervals (CI) were calculated. Probability (p) values for changes in DAS28 scores were calculated by the t test. The predictive value of baseline sIL2R level for change in DAS28 score at six and 22 weeks was calculated by robust regression analysis. This type of regression analysis, in which the weight given to outliers is reduced, is appropriate for analysis of small datasets because it makes the results less sensitive to the presence of outliers.

RESULTS
Table 1 presents the characteristics of the patients and table 2 the DMARDs used by the patients. The mean (SD) serum sIL2R was 621 (325) U/ml, and the DAS28 score, 6.3 (1.0). The serum sIL2R level did not correlate with the baseline DAS28 score (r = 0.24 (95% CI, −0.18 to 0.58)). There was a distinct clinical response to infliximab. At six weeks, DAS28 scores improved (mean (SD) score, 3.7 (1.7)), with a mean change of −2.53 (95% CI, −3.08 to −1.95) (p<0.001). This change was predicted by baseline sIL2R level (table 3; fig 1A) but not by baseline DAS28 score or infliximab dose. At 22 weeks, the mean DAS28 score was 4.0 (1.2), and the mean change from baseline was −2.26 (−2.75 to −1.77) (p<0.001). This change was predicted by neither the baseline sIL2R level (table 3; fig 1B) nor the baseline DAS28 score or infliximab dose.

In four patients initially receiving a combination of DMARDs the treatment regimen was tapered as their clinical condition improved during the infliximab treatment. One patient had a temporary pause in the methotrexate treatment because of raised liver enzyme levels.

DISCUSSION
The results show that low serum sIL2R level predicts early (six weeks) response to infliximab treatment. To the best of our knowledge such a predictor for early response has not been described before. Given that the serum sIL2R level serves as a marker to T cell activation, our results suggest that enhanced T cell activation is related to delayed response to the infliximab treatment. This suggestion emphasises the impact of lymphocytes on the rheumatic inflammation and is supported by at least two lines of evidence.

First, about one third of patients with rheumatoid arthritis have extensive lymphocytic infiltration in the synovium with T and B cell conglomerates, sometimes forming germinal centres. Such patients have a more active disease and higher levels of sIL2R in their sera. Consequently, the patients with high baseline sIL2R may have large numbers of activated T cells in the synovium, thus requiring several infliximab infusions before the synovial infiltrate is reduced and disease activity is lowered.

Second, we have previously investigated chemokine receptor expression on circulating lymphocytes in the same patients. The patients responding to infliximab (fulfilling the ACR20 response) had smaller numbers of T cells expressing...
Table 3  Baseline adjusted robust regression for baseline serum soluble interleukin 2 receptor (sIL2R) predicting change in 28 joint disease activity score (DAS28) after six and 22 weeks

<table>
<thead>
<tr>
<th>Explantory variable</th>
<th>After 6 weeks</th>
<th>p Value</th>
<th>After 22 weeks</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline sIL2R (per 100 U/ml)</td>
<td>0.2054 (0.0035 to 0.4073)</td>
<td>0.047</td>
<td>0.0152 (0.0182 to 0.2176)</td>
<td>0.87</td>
</tr>
<tr>
<td>Baseline DAS28 score</td>
<td>0.0383 (0.5237 to 0.6498)</td>
<td>0.84</td>
<td>-0.4067 (0.8730 to 0.2593)</td>
<td>0.27</td>
</tr>
<tr>
<td>Infliximab dose (mg/kg)</td>
<td>0.1313 (0.3719 to 0.6346)</td>
<td>0.59</td>
<td>0.0185 (0.4515 to 0.4858)</td>
<td>0.94</td>
</tr>
<tr>
<td>Constant</td>
<td>-0.995 (0.9708 to -1.2823)</td>
<td>-0.731 (0.220 to 2.873)</td>
<td>-0.731 (0.220 to 2.873)</td>
<td>-0.731 (0.220 to 2.873)</td>
</tr>
</tbody>
</table>

ACKNOWLEDGEMENTS

Supported by grants from Finnish Cultural Foundation, Paulo Foundation, and Helsinki University Central Hospital research funds.

Authors’ affiliations

A Kuuliala, Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland
R Nissinen, Department of Molecular Medicine, National Public Health Institute, Helsinki
H Kautiainen, Rheumatism Foundation Hospital, Heinola, Finland
H Repo, Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital
M Leirisalo-Reponen, Division of Rheumatology, Department of Medicine, Helsinki University Central Hospital

REFERENCES


